{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=18&state=Colorado",
    "query": {
      "state": "Colorado",
      "city": "Aurora",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 7436,
    "total_pages": 744,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=19&state=Colorado&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=17&state=Colorado&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T11:14:15.940Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00978458",
      "title": "Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Neurotoxicity"
      ],
      "interventions": [
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "3-dimensional conformal radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "intensity-modulated radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 540,
      "start_date": "2009-11-17",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-03T11:14:15.940Z",
      "location_count": 168,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00978458"
    },
    {
      "nct_id": "NCT02823145",
      "title": "An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "ZX008 (Fenfluramine Hydrochloride)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "2 Years to 35 Years"
      },
      "enrollment_count": 375,
      "start_date": "2016-06-08",
      "completion_date": "2023-01-27",
      "has_results": true,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-11-03T11:14:15.940Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Orange, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02823145"
    },
    {
      "nct_id": "NCT01842581",
      "title": "The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatic Encephalopathy",
        "Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Lactulose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 222,
      "start_date": "2013-01-08",
      "completion_date": "2014-12-17",
      "has_results": true,
      "last_update_posted_date": "2019-09-09",
      "last_synced_at": "2026-11-03T11:14:15.940Z",
      "location_count": 43,
      "location_summary": "Phoenix, Arizona • Coronado, California • Fresno, California + 35 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01842581"
    },
    {
      "nct_id": "NCT00538434",
      "title": "Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "Reslizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Ception Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "5 Years to 18 Years"
      },
      "enrollment_count": 227,
      "start_date": "2008-03",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2016-09-02",
      "last_synced_at": "2026-11-03T11:14:15.940Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00538434"
    },
    {
      "nct_id": "NCT04803214",
      "title": "ReActiv8 Stimulation Therapy vs Optimal Medical Management: A Randomized Evaluation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Low-back Pain"
      ],
      "interventions": [
        {
          "name": "ReActiv8",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Mainstay Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 203,
      "start_date": "2021-07-14",
      "completion_date": "2026-01-05",
      "has_results": true,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-11-03T11:14:15.940Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04803214"
    },
    {
      "nct_id": "NCT02177136",
      "title": "Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Sclerosing Cholangitis (PSC)"
      ],
      "interventions": [
        {
          "name": "Obeticholic Acid (OCA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 77,
      "start_date": "2015-02-09",
      "completion_date": "2018-03-22",
      "has_results": true,
      "last_update_posted_date": "2021-07-08",
      "last_synced_at": "2026-11-03T11:14:15.940Z",
      "location_count": 33,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02177136"
    },
    {
      "nct_id": "NCT06443463",
      "title": "Long-term Safety and Tolerability of BHV-7000",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Epilepsy"
      ],
      "interventions": [
        {
          "name": "BHV-7000",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biohaven Therapeutics Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 660,
      "start_date": "2024-07-30",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-11-03T11:14:15.940Z",
      "location_count": 115,
      "location_summary": "Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 92 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06443463"
    },
    {
      "nct_id": "NCT02003209",
      "title": "Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HER2-Positive Breast Carcinoma",
        "Hormone Receptor-Positive Breast Carcinoma",
        "Stage IB Breast Cancer AJCC v7",
        "Stage IIA Breast Cancer AJCC v6 and v7",
        "Stage IIB Breast Cancer AJCC v6 and v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Aromatase Inhibition Therapy",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cytology Specimen Collection Procedure",
          "type": "OTHER"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Goserelin Acetate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Whole Breast Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 315,
      "start_date": "2014-02-18",
      "completion_date": "2025-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-03T11:14:15.940Z",
      "location_count": 731,
      "location_summary": "Fairbanks, Alaska • Hot Springs, Arkansas • Anaheim, California + 466 more",
      "locations": [
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Antioch",
          "state": "California"
        },
        {
          "city": "Arroyo Grande",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02003209"
    },
    {
      "nct_id": "NCT01945593",
      "title": "BAX 855 Continuation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "BAX855",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 218,
      "start_date": "2013-10-15",
      "completion_date": "2018-03-02",
      "has_results": true,
      "last_update_posted_date": "2021-05-24",
      "last_synced_at": "2026-11-03T11:14:15.940Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01945593"
    },
    {
      "nct_id": "NCT01527006",
      "title": "Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Nervous System"
      ],
      "interventions": [
        {
          "name": "perampanel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "2 Years to 11 Years"
      },
      "enrollment_count": 63,
      "start_date": "2012-01",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-07-12",
      "last_synced_at": "2026-11-03T11:14:15.940Z",
      "location_count": 23,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Gulf Breeze, Florida + 20 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01527006"
    }
  ]
}